Trajan Group Holdings Limited
TRJ.ASXHealth Care
Development and manufacture of analytical and life sciences instruments and devices.
Market Data
$0.315
-0.1%$51.1M
-100000.0x
$-0.009
0.00%
-0.5%
Latest Earnings
H1 FY26 Financial Results Release
26 February 2026
Trajan Group reported H1 FY26 revenue of $84.1M (up 3.8%) but normalised EBITDA fell 36.2% to $5.0M due to FX impacts, tariff-related costs, and regional expansion expenses. Despite the challenging first half, management maintained full-year guidance expecting revenue to exceed $170M and nEBITDA to exceed $16M. Key points: Record Q2 revenue of $45.4M showing strong momentum building into H2; Components & Consumables segment showed resilience with 6.1% revenue growth to $51.9M; Disruptive Technologies segment achieved 40.2% revenue growth and 69.4% improvement in nEBITDA
Recent Announcements
Trading Update - Operational initiatives, AUD revaluation H2
Trajan Group Holdings Limited (ASX: TRJ) issued a trading update confirming H2 FY26 market demand and operational initiatives are on track, but noted that Australian dollar appreciation is likely to reduce reported results by approximately $4.0M in Revenue and $2.0M in nEBITDA, though the company's cash position is protected through FX hedging contracts to June 2027.
H1 FY26 Financial Results Release
Trajan Group reported H1 FY26 revenue of $84.1M (up 3.8%) but normalised EBITDA fell 36.2% to $5.0M due to FX impacts, tariff-related costs, and regional expansion expenses. Despite the challenging first half, management maintained full-year guidance expecting revenue to exceed $170M and nEBITDA to exceed $16M. Key points: Record Q2 revenue of $45.4M showing strong momentum building into H2; Components & Consumables segment showed resilience with 6.1% revenue growth to $51.9M; Disruptive Technologies segment achieved 40.2% revenue growth and 69.4% improvement in nEBITDA
H1 FY26 Financial Results Presentation
Trajan Scientific and Medical reported H1 FY26 results with revenue up 3.8% to $84.1M but nEBITDA down 36.2% to $5.0M, citing macroeconomic headwinds, tariff impacts, and margin pressures from regional expansion; the company maintained FY26 guidance of $170M+ revenue and $16M+ nEBITDA, expecting recovery in H2 from cost reductions and pricing actions.
H1 FY26 Appendix 4D and Interim Report
Trajan Group delivered modest revenue growth of 3.8% to $84.1M for H1 FY26, driven by strong Components & Consumables performance (+6.1%) offsetting weakness in Capital Equipment (-2.7%). However, normalised EBITDA fell significantly from $7.9M to $5.0M as margins compressed across most segments due to higher costs and timing issues. Key points: Components & Consumables segment showed resilience with 6.1% revenue growth to $51.9M; Disruptive Technologies segment delivered strong 40.2% revenue growth to $3.1M with 50.7% gross margin; Maintained global manufacturing footprint with over 630 employees across seven manufacturing sites
Get real-time alerts for TRJ
Receive AI-powered earnings summaries and instant notifications when Trajan Group Holdings Limited releases results.
Register Free